A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Mesothelin-specific Chimeric Antigen Receptor (CAR)-positive T-Cells in Patients with Metastatic Mesothelin-expressing Breast Cancer
A protein called mesothelin is overexpressed in some breast cancers. In this study, researchers are seeking to find the highest dose of genetically modified T cells (a type of white blood cell) that can be used to treat patients with metastatic HER2-negative breast cancer that has continued to grow despite therapy.
The treatment involves utilizing a patient's own T cells and genetically modifying them in the laboratory to recognize mesothelin. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancerous cells throughout the body. This approach is a form of immunotherapy.
Patients will receive the treatment intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have metastatic HER2-negative breast cancer that has continued to grow despite at least one prior regimen of therapy.
- Patients must recover from the serious side effects of prior treatments before entering the study.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Prasad Adusumilli at 212-639-8093.